ATC Group: M03BC01 Orphenadrine (citrate)

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of M03BC01 in the ATC hierarchy

Level Code Title
1 M Musculo-skeletal system
2 M03 Muscle relaxants
3 M03B Muscle relaxants, centrally acting agents
4 M03BC Ethers, chemically close to antihistamines
5 M03BC01 Orphenadrine (citrate)

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 0.12 g
PAREN - Parenteral 0.12 g

Active ingredients in M03BC01

Active Ingredient Description
Orphenadrine

Orphenadrine, which is a congener of diphenhydramine without sharing its soporific effect, is an anti-muscarinic agent. Orphenadrine is used as the hydrochloride in the symptomatic treatment of Parkinsonism.

Medicines in this ATC group

Canada (CA)

Finland (FI)

Hong Kong (HK)

New Zealand (NZ)

Nigeria (NG)

Singapore (SG)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.